PRTC
PureTech Health plc
Biotechnology
Market Cap$41M
5Y Perf.-68.6%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
PRTC vs ROIV
Revenue, margins, valuation, and 5-year total return — side by side.
ROIV
Roivant Sciences Ltd.
Biotechnology
Market Cap$20.51B
5Y Perf.+178.1%
PRTC vs ROIV — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | PRTC | ROIV |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $41M | $20.51B |
| Revenue (TTM) | $9M | $13M |
| Net Income (TTM) | $-56M | $-809M |
| Gross Margin | -196.2% | 91.2% |
| Operating Margin | -26.2% | -91.3% |
| Total Debt | $20M | $100M |
| Cash & Equiv. | $254M | $2.72B |
PRTC vs ROIV — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
PRTC
ROIV
| Stock | Dec 20 | May 26 | Return |
|---|---|---|---|
| PureTech Health plc (PRTC) | 100 | 31.4 | -68.6% |
| Roivant Sciences Lt… (ROIV) | 100 | 278.1 | +178.1% |
Price return only. Dividends and distributions are not included.
Quick Verdict: PRTC vs ROIV
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: PRTC leads in 4 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Roivant Sciences Ltd. is the stronger pick specifically for recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
PRTC
PureTech Health plc
The Income Pick
PRTC carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 1 yrs, beta 0.51
- Rev growth -3.5%, EPS growth -24.0%, 3Y rev CAGR 30.6%
- Lower volatility, beta 0.51, Low D/E 6.5%, current ratio 6.59x
Best for: income & stability and growth exposure
ROIV
Roivant Sciences Ltd.
The Long-Run Compounder
ROIV is the clearest fit if your priority is long-term compounding.
- 171.9% 10Y total return vs PRTC's -55.9%
- +153.2% vs PRTC's -2.6%
Best for: long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | PRTC | -3.5% revenue growth vs ROIV's -11.2% |
| Quality / Margins | PRTC | -6.2% margin vs ROIV's -60.8% |
| Stability / Safety | PRTC | Beta 0.51 vs ROIV's 0.95 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | ROIV | +153.2% vs PRTC's -2.6% |
| Efficiency (ROA) | PRTC | -9.9% ROA vs ROIV's -15.5%, ROIC -66.9% vs -50.4% |
PRTC vs ROIV — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2024
PRTC vs ROIV — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLPRTCLAGGINGROIV
ROIVRoivant Sciences Ltd.
2leads
PRTCPureTech Health plc
2leads
6 Total Categories
CATEGORYLEADERvs ROIVMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
PRTC4/6
Valuation MetricsMultiples, price ratios, and targets
PRTC2/3
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
ROIV4/7
Total Returns1Y, 3Y, 5Y total returns with dividends
ROIV6/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
PRTC leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
ROIV and PRTC operate at a comparable scale, with $13M and $9M in trailing revenue. PRTC is the more profitable business, keeping -6.2% of every revenue dollar as net income compared to ROIV's -60.8%. On growth, PRTC holds the edge at -30.5% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | PRTCPureTech Health p… | ROIVRoivant Sciences … |
|---|---|---|
| RevenueTrailing 12 months | $9M | $13M |
| EBITDAEarnings before interest/tax | -$228M | -$1.2B |
| Net IncomeAfter-tax profit | -$56M | -$809M |
| Free Cash FlowCash after capex | -$219M | -$767M |
| Gross MarginGross profit ÷ Revenue | -196.2% | +91.2% |
| Operating MarginEBIT ÷ Revenue | -26.2% | -91.3% |
| Net MarginNet income ÷ Revenue | -6.2% | -60.8% |
| FCF MarginFCF ÷ Revenue | -24.4% | -57.6% |
| Rev. Growth (YoY)Latest quarter vs prior year | -30.5% | -77.8% |
| EPS Growth (YoY)Latest quarter vs prior year | -8.7% | -2.7% |
PRTC leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
PRTC leads this category, winning 2 of 3 comparable metrics.
Valuation Metrics
| Metric | PRTCPureTech Health p… | ROIVRoivant Sciences … |
|---|---|---|
| Market CapShares × price | $41M | $20.5B |
| Enterprise ValueMkt cap + debt − cash | -$193M | $17.9B |
| Trailing P/EPrice ÷ TTM EPS | -0.37x | -117.83x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 8.79x | 706.10x |
| Price / BookPrice ÷ Book value/share | 0.13x | 3.95x |
| Price / FCFMarket cap ÷ FCF | — | — |
PRTC leads this category, winning 2 of 3 comparable metrics.
Profitability & Efficiency
ROIV leads this category, winning 4 of 7 comparable metrics.
Profitability & Efficiency
PRTC delivers a -16.1% return on equity — every $100 of shareholder capital generates $-16 in annual profit, vs $-16 for ROIV. ROIV carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to PRTC's 0.06x.
| Metric | PRTCPureTech Health p… | ROIVRoivant Sciences … |
|---|---|---|
| ROE (TTM)Return on equity | -16.1% | -16.3% |
| ROA (TTM)Return on assets | -9.9% | -15.5% |
| ROICReturn on invested capital | -66.9% | -50.4% |
| ROCEReturn on capital employed | -18.8% | -16.4% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 5 |
| Debt / EquityFinancial leverage | 0.06x | 0.02x |
| Net DebtTotal debt minus cash | -$234M | -$2.6B |
| Cash & Equiv.Liquid assets | $254M | $2.7B |
| Total DebtShort + long-term debt | $20M | $100M |
| Interest CoverageEBIT ÷ Interest expense | -1.16x | — |
ROIV leads this category, winning 4 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
ROIV leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ROIV five years ago would be worth $28,537 today (with dividends reinvested), compared to $2,988 for PRTC. Over the past 12 months, ROIV leads with a +153.2% total return vs PRTC's -2.6%. The 3-year compound annual growth rate (CAGR) favors ROIV at 46.7% vs PRTC's -16.3% — a key indicator of consistent wealth creation.
| Metric | PRTCPureTech Health p… | ROIVRoivant Sciences … |
|---|---|---|
| YTD ReturnYear-to-date | +2.0% | +29.0% |
| 1-Year ReturnPast 12 months | -2.6% | +153.2% |
| 3-Year ReturnCumulative with dividends | -41.3% | +215.6% |
| 5-Year ReturnCumulative with dividends | -70.1% | +185.4% |
| 10-Year ReturnCumulative with dividends | -55.9% | +171.9% |
| CAGR (3Y)Annualised 3-year return | -16.3% | +46.7% |
ROIV leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
Evenly matched — PRTC and ROIV each lead in 1 of 2 comparable metrics.
Risk & Volatility
PRTC is the less volatile stock with a 0.51 beta — it tends to amplify market swings less than ROIV's 0.95 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ROIV currently trades 93.2% from its 52-week high vs PRTC's 85.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | PRTCPureTech Health p… | ROIVRoivant Sciences … |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.51x | 0.95x |
| 52-Week HighHighest price in past year | $19.92 | $30.33 |
| 52-Week LowLowest price in past year | $14.50 | $10.58 |
| % of 52W HighCurrent price vs 52-week peak | +85.2% | +93.2% |
| RSI (14)Momentum oscillator 0–100 | 48.2 | 54.8 |
| Avg Volume (50D)Average daily shares traded | 8K | 4.8M |
Evenly matched — PRTC and ROIV each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates PRTC as "Buy" and ROIV as "Buy". Consensus price targets imply 235.9% upside for PRTC (target: $57) vs 17.4% for ROIV (target: $33).
| Metric | PRTCPureTech Health p… | ROIVRoivant Sciences … |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $57.00 | $33.20 |
| # AnalystsCovering analysts | 2 | 14 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 1 | 1 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +5.0% | +6.3% |
Insufficient data to determine a leader in this category.
Key Takeaway
PRTC leads in 2 of 6 categories (Income & Cash Flow, Valuation Metrics). ROIV leads in 2 (Profitability & Efficiency, Total Returns). 1 tied.
Best OverallPureTech Health plc (PRTC)Leads 2 of 6 categories
Loading custom metrics...
PRTC vs ROIV: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is PRTC or ROIV a better buy right now?
For growth investors, PureTech Health plc (PRTC) is the stronger pick with -3.
5% revenue growth year-over-year, versus -11. 2% for Roivant Sciences Ltd. (ROIV). Analysts rate PureTech Health plc (PRTC) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — PRTC or ROIV?
Over the past 5 years, Roivant Sciences Ltd.
(ROIV) delivered a total return of +185. 4%, compared to -70. 1% for PureTech Health plc (PRTC). Over 10 years, the gap is even starker: ROIV returned +171. 9% versus PRTC's -55. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — PRTC or ROIV?
By beta (market sensitivity over 5 years), PureTech Health plc (PRTC) is the lower-risk stock at 0.
51β versus Roivant Sciences Ltd. 's 0. 95β — meaning ROIV is approximately 88% more volatile than PRTC relative to the S&P 500. On balance sheet safety, Roivant Sciences Ltd. (ROIV) carries a lower debt/equity ratio of 2% versus 6% for PureTech Health plc — giving it more financial flexibility in a downturn.
04Which is growing faster — PRTC or ROIV?
By revenue growth (latest reported year), PureTech Health plc (PRTC) is pulling ahead at -3.
5% versus -11. 2% for Roivant Sciences Ltd. (ROIV). On earnings-per-share growth, the picture is similar: Roivant Sciences Ltd. grew EPS -104. 6% year-over-year, compared to -24. 0% for PureTech Health plc. Over a 3-year CAGR, PRTC leads at 30. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — PRTC or ROIV?
Roivant Sciences Ltd.
(ROIV) is the more profitable company, earning -592. 0% net margin versus -23. 6% for PureTech Health plc — meaning it keeps -592. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PRTC leads at -21. 1% versus -34. 5% for ROIV. At the gross margin level — before operating expenses — PRTC leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — PRTC or ROIV?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is PRTC or ROIV better for a retirement portfolio?
For long-horizon retirement investors, PureTech Health plc (PRTC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
51)). Both have compounded well over 10 years (PRTC: -55. 9%, ROIV: +171. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between PRTC and ROIV?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(PRTC: -30.5% · ROIV: -77.8%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.